Crinetics Pharmaceuticals, Inc. Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals, Inc.

CRNX

Rang în acțiuni #2239
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Preț acțiune
$84.95
Ultima sincronizare: 2026-09-01
Capitalizare de piață
$9.00B
Schimbare (1 zi)
0.00%
Schimbare (1 an)
98.25%
Țară
US
Tranzacționează Crinetics Pharmaceuticals, Inc. (CRNX)

Categorie

Healthcare
Istoricul spliturilor pentru Crinetics Pharmaceuticals, Inc. (CRNX)
Acțiunea Crinetics Pharmaceuticals, Inc. (simbol: CRNX) a trecut printr-un total de 0 splituri.
Cel mai recent split a avut loc pe Oct 21, 2026.
O acțiune CRNX cumpărată înainte de Oct 21, 2026 este echivalentă astăzi cu 0 acțiuni CRNX.
Listă splituri acțiuni
An Split Multiplu Multiplu cumulativ
Nu sunt suficiente date pentru perioada selectată.
Splituri pentru companii similare sau competitori
Companie Număr total de splituri Multiplu cumulativ Țara
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL